PROSTAGRAM

Prostate Cancer Screening Trial using A Group of Radiological Approaches including MRI and ultrasound

Design and Objective

This is a prospective, population-based, paired screening positive cohort study investigating a fast MRI scan in comparison to PSA for prostate cancer screening. The study is designed to determine the positive test rate of MRI at different thresholds. Secondary objectives include the proportion diagnosed with clinically-significant and insignificant prostate cancer and point estimates for sensitivity, specificity, PPV and NPV.

Key inclusion criteria

Men aged 50-69 years without a recent history of previous PSA screening tests or prostate cancer. No evidence of a urinary tract infection or history of acute prostatitis within the last 6 months or contraindication to MRI.

Study Disclaimer Statement

The PROSTAGRAM trial is funded by a Wellcome Trust Programme Grant (grant number 204998/Z/16/Z), a BMA Foundation for Medical Research grant, a Urology Foundation Research Scholarship (RESCH18), a Royal College of Surgeons of England Research Fellowship and a grant from UK National Institute of Health Research Imperial Biomedical Research Centre.